

Armin Zebisch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4723153/publications.pdf>

Version: 2024-02-01

64
papers

1,340
citations

393982

19
h-index

377514

34
g-index

65
all docs

65
docs citations

65
times ranked

2437
citing authors

#	ARTICLE	IF	CITATIONS
1	Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. <i>Nature Communications</i> , 2019, 10, 4666.	5.8	146
2	Signaling Through RAS-RAF-MEK-ERK: from Basics to Bedside. <i>Current Medicinal Chemistry</i> , 2007, 14, 601-623.	1.2	102
3	Germline mutations in the DNA damage response genes <i>BRCA1</i> , <i>BRCA2</i> , <i>BARD1</i> and <i>TP53</i> in patients with therapy related myeloid neoplasms. <i>Journal of Medical Genetics</i> , 2012, 49, 422-428.	1.5	87
4	Two Transforming C-RAF Germ-Line Mutations Identified in Patients with Therapy-Related Acute Myeloid Leukemia. <i>Cancer Research</i> , 2006, 66, 3401-3408.	0.4	84
5	Clinical implications of subclonal <i>TP53</i> mutations in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 516-523.	1.7	65
6	Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2080.	1.8	58
7	Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia. <i>Clinical Epigenetics</i> , 2021, 13, 1.	1.8	57
8	Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. <i>Blood</i> , 2017, 130, 946-948.	0.6	52
9	Germline variants in the <i>SEMA4A</i> gene predispose to familial colorectal cancer type X. <i>Nature Communications</i> , 2014, 5, 5191.	5.8	51
10	Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP. <i>Cancer Research</i> , 2016, 76, 3644-3654.	0.4	45
11	Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. <i>International Journal of Molecular Sciences</i> , 2017, 18, 415.	1.8	45
12	Somatic <i>TP53</i> mutations characterize preleukemic stem cells in acute myeloid leukemia. <i>Blood</i> , 2017, 129, 2587-2591.	0.6	44
13	Functional Classification of <i>TP53</i> Mutations in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 637.	1.7	42
14	Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. <i>Leukemia and Lymphoma</i> , 2018, 59, 501-504.	0.6	41
15	Acute myeloid leukemia with <i>TP53</i> germ line mutations. <i>Blood</i> , 2016, 128, 2270-2272.	0.6	39
16	Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. <i>Journal of Hematology and Oncology</i> , 2016, 9, 39.	6.9	36
17	Identification of a novel variant of epsilon γ delta β thalassemia highlights limitations of next generation sequencing. <i>American Journal of Hematology</i> , 2015, 90, E52-4.	2.0	24
18	High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34 ϵ positive AML. <i>Cancer Medicine</i> , 2019, 8, 1771-1778.	1.3	22

#	ARTICLE	IF	CITATIONS
19	Evidence for a role of decitabine in the treatment of myeloid sarcoma. <i>Annals of Hematology</i> , 2017, 96, 505-506.	0.8	20
20	The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML). <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 410-418.	1.0	18
21	Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis. <i>Leukemia Research</i> , 2016, 42, 47-51.	0.4	17
22	Highly Expressed miR-375 is not an Intracellular Oncogene in Merkel Cell Polyomavirus-Associated Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 529.	1.7	17
23	Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 23-30.	2.0	16
24	miR-181a Modulation of ERK-MAPK Signaling Sustains DC-SIGN Expression and Limits Activation of Monocyte-Derived Dendritic Cells. <i>Cell Reports</i> , 2020, 30, 3793-3805.e5.	2.9	14
25	Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1186-1192.	2.0	13
26	Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling. <i>American Journal of Hematology</i> , 2020, 95, 1148-1157.	2.0	13
27	Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 496.	1.7	12
28	Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis. <i>Haematologica</i> , 2020, 105, 375-386.	1.7	11
29	Acute Myeloid Leukemia and Myelodysplastic Syndromes with <i>TP53</i> Aberrations – A Distinct Stem Cell Disorder. <i>Clinical Cancer Research</i> , 2020, 26, 5304-5309.	3.2	11
30	Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia – A Retrospective Analysis in 337 Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3025.	1.8	11
31	Mutations in DNMT3A and loss of RKIP are independent events in acute monocytic leukemia. <i>Haematologica</i> , 2012, 97, 1936-1937.	1.7	10
32	Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration. <i>Blood</i> , 2018, 131, 826-830.	0.6	10
33	Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. <i>European Journal of Haematology</i> , 2021, 107, 265-274.	1.1	10
34	Severe Hemolysis As Presenting Sign of Acute Erythroleukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 330-331.	0.8	8
35	Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation. <i>PLoS ONE</i> , 2015, 10, e0129859.	1.1	8
36	Feasibility and safety of using an automated decision support system for insulin therapy in the treatment of steroid-induced hyperglycemia in patients with acute graft-versus-host disease: A randomized trial. <i>Journal of Diabetes Investigation</i> , 2019, 10, 339-342.	1.1	8

#	ARTICLE	IF	CITATIONS
37	Pulmonary arterial pressure in patients with myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2016, 57, 2723-2726.	0.6	7
38	RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5756.	1.8	6
39	Deletion of SPRY4 is a frequent event in secondary acute myeloid leukemia. <i>Annals of Hematology</i> , 2015, 94, 1923-1924.	0.8	5
40	Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6057.	1.8	5
41	TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model. <i>Annals of Hematology</i> , 2020, 99, 653-655.	0.8	5
42	Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data. <i>Blood</i> , 2015, 126, 2515-2515.	0.6	5
43	Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations. <i>Annals of Hematology</i> , 2022, 101, 837-846.	0.8	5
44	Detection of AML-specific TP53 mutations in bone marrow-derived mesenchymal stromal cells cultured under hypoxia conditions. <i>Annals of Hematology</i> , 2019, 98, 2019-2020.	0.8	4
45	The miR-424(322)/503 gene cluster regulates pro- versus anti-inflammatory skin DC subset differentiation by modulating TGF- β 2 signaling. <i>Cell Reports</i> , 2021, 35, 109049.	2.9	4
46	Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group. <i>Cancers</i> , 2022, 14, 2459.	1.7	4
47	Are mouthwashes a reliable source of constitutional DNA in patients with leukemia?. <i>Leukemia Research</i> , 2008, 32, 1164-1165.	0.4	3
48	The role of germline mutation profiling in the selection of related donors for haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1502-1505.	1.3	3
49	TNF \pm Rescues Dendritic Cell Development in Hematopoietic Stem and Progenitor Cells Lacking C/EBP \pm . <i>Cells</i> , 2020, 9, 1223.	1.8	3
50	EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity. <i>Leukemia</i> , 2021, 35, 1521-1526.	3.3	3
51	Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?. <i>Blood</i> , 2015, 126, 3742-3742.	0.6	3
52	Multistep pathogenesis of chronic myelomonocytic leukemia in patients. <i>European Journal of Haematology</i> , 2022, , .	1.1	3
53	The Role of Immunohistochemical Overexpression of p53 as Adverse Prognostic Factor in Primary Testicular Diffuse Large B Cell Lymphoma. <i>Pathology and Oncology Research</i> , 2020, 26, 2831-2833.	0.9	2
54	miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms. <i>Annals of Hematology</i> , 2021, 100, 2845-2847.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Functional Classification of TP53 Mutations in Acute Myeloid Leukemia. Blood, 2019, 134, 2725-2725.	0.6	1
56	Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. Wiener Klinische Wochenschrift, 2018, 130, 115-125.	1.0	0
57	Two Novel Activating Germline Mutations of the C-RAF Proto-Oncogene Predisposing to Solid Tumors and Therapy-Related Acute Myeloid Leukemia.. Blood, 2004, 104, 3370-3370.	0.6	0
58	Adding Palifermin in Allogeneic and Autologous Stem Cell Transplantation Resulted in Reduced Oral Mucositis and Enhanced Intestinal Mucosal Recovery Measured by Citrulline Serum Levels.. Blood, 2006, 108, 5251-5251.	0.6	0
59	Base Excision Repair Glycosylase Activity Is Impaired in a Subgroup of Acute Myeloid Leukemia Resulting in Increased Levels of Oxidative Base Lesions. Blood, 2014, 124, 860-860.	0.6	0
60	Clinical, Hematological, and Biologic Characteristics in Chronic Myelomonocytic Leukemia Patients with a JAK2 V617F Mutation. Blood, 2016, 128, 3189-3189.	0.6	0
61	High Spontaneous In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia is Associated with Mutations in Rasopathy Genes, Myeloproliferation and Inferior Prognosis. Blood, 2016, 128, 5503-5503.	0.6	0
62	Impact of TP53 Mutated Subclones in Acute Myeloid Leukemia. Blood, 2018, 132, 1483-1483.	0.6	0
63	The role of RAF kinase inhibitor protein in hematologic malignancies. , 2020, , 127-136.		0
64	How do non-coding RNAs impact treatment regimens currently being used in AML?. Expert Review of Anticancer Therapy, 2022, 22, 331-333.	1.1	0